Business Description
NovaBridge Biosciences
ISIN : US44975P1030
Share Class Description:
STU:0VY: ADRTotal Employee Number:
30Description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 68.75 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15.9 | |||||
3-Year EPS without NRI Growth Rate | 50.2 | |||||
3-Year FCF Growth Rate | 30 | |||||
3-Year Book Growth Rate | -26.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -8.95 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.41 | |||||
9-Day RSI | 40.42 | |||||
14-Day RSI | 44.46 | |||||
3-1 Month Momentum % | -38.99 | |||||
6-1 Month Momentum % | -58.95 | |||||
12-1 Month Momentum % | -24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.09 | |||||
Quick Ratio | 8.09 | |||||
Cash Ratio | 7.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | -30.51 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -21.3 | |||||
ROA % | -19.84 | |||||
ROIC % | -222.38 | |||||
3-Year ROIIC % | 204.39 | |||||
ROC (Joel Greenblatt) % | -2791.5 | |||||
ROCE % | -42.86 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.87 | |||||
Price-to-Tangible-Book | 0.87 | |||||
EV-to-EBIT | 0.08 | |||||
EV-to-EBITDA | 0.08 | |||||
EV-to-Forward-Revenue | 1.8 | |||||
EV-to-FCF | 0.35 | |||||
| Price-to-Net-Current-Asset-Value | 1.06 | |||||
| Price-to-Net-Cash | 1.1 | |||||
Earnings Yield (Greenblatt) % | 1250 | |||||
FCF Yield % | -10.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NovaBridge Biosciences Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.417 | ||
| Beta | 1.2512 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.39 | ||
| Volatility % | 120.88 | ||
| 14-Day RSI | 44.46 | ||
| 14-Day ATR (€) | 0.096274 | ||
| 20-Day SMA (€) | 1.6225 | ||
| 12-1 Month Momentum % | -24 | ||
| 52-Week Range (€) | 1.25 - 5.7 | ||
| Shares Outstanding (Mil) | 115.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NovaBridge Biosciences Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NovaBridge Biosciences Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 28 days | ||
| First quarter earnings results for 2026 | 2026-07-24 | In 1 day | ||
| Guidance call for 2026 | 2026-06-04 15:10 | 1.49 (+2.76%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 15:30 | 1.47 (-3.92%) | ||
| Annual report for 2025 | 2026-04-07 | 2.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-07 | 2.06 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-11 08:00 | 2.74 (-7.43%) | ||
| virtual business update call | 2026-03-09 09:00 | 2.98 (-1.97%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-10 09:30 | 3.86 (+9.04%) |
Show
Entries
NovaBridge Biosciences Frequently Asked Questions
What is NovaBridge Biosciences(STU:0VY)'s stock price today?
The current price of STU:0VY is €1.50. The 52 week high of STU:0VY is €5.70 and 52 week low is €1.25.
When is next earnings date of NovaBridge Biosciences(STU:0VY)?
The next earnings date of NovaBridge Biosciences(STU:0VY) is 2026-07-24 Est..
Does NovaBridge Biosciences(STU:0VY) pay dividends? If so, how much?
NovaBridge Biosciences(STU:0VY) does not pay dividend.
Press Release
Articles on NovaBridge Biosciences
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers